Edrophonium Chloride
Title: Edrophonium Chloride
CAS Registry Number: 116-38-1
CAS Name: N-Ethyl-3-hydroxy-N,N-dimethylbenzenaminium chloride
Additional Names: ethyl(m-hydroxyphenyl)dimethylammonium chloride; (3-hydroxyphenyl)dimethylethylammonium chloride; 3-hydroxy-N,N-dimethyl-N-ethylanilinium chloride
Trademarks: Antirex (Kyorin); Enlon (Ohmeda); Reversol (Organon); Tensilon (Valeant)
Molecular Formula: C10H16ClNO
Molecular Weight: 201.69
Percent Composition: C 59.55%, H 8.00%, Cl 17.58%, N 6.94%, O 7.93%
Literature References: Cholinesterase inhibitor. Prepn: J. A. Aeschlimann, A. Stempel, US 2647924 (1953 to Hoffmann-La Roche). LC determn in biological fluids: M. G. M. DeRuyter et al., J. Chromatogr. 183, 193 (1980). Clinical evaluation in reversal of neuromuscular blockade: D. M. Fisher et al., Anesthesiology 61, 428 (1984). Clinical study in supraventricular tachycardia: J. D. Cantwell et al., Arch. Int. Med. 130, 221 (1972). Diagnostic use in myasthenia gravis: I. M. Williams et al., Clin. Exp. Neurol. 22, 1 (1986); in esophageal chest pain: C. A. Lee et al., Dig. Dis. Sci. 32, 682 (1987).
Properties: Crystals from isopropanol, dec 162-163°. pH of 1% aq soln 4-5. Very sol in water; freely sol in alcohol. Insol in chloroform, ether.
 
Derivative Type: Edrophonium Bromide
Additional Names: Edrophone bromide
Manufacturers' Codes: Ro-2-3198
Molecular Formula: C10H16BrNO
Molecular Weight: 246.14
Percent Composition: C 48.80%, H 6.55%, Br 32.46%, N 5.69%, O 6.50%
Properties: Crystals from ethanol + ether, dec 151-152°. Bitter taste. Sol in water (more than 10%). Moderately sol in alcohol. Practically insol in ether. Solns are stable.
 
Therap-Cat: Cholinergic; antidote to curare; diagnostic aid (myasthenia gravis).
Keywords: Antidote (Curare); Cholinergic; Diagnostic Aid.

Others monographs:
AntheridiolHydroorotic AcidHydrazine HydrateDomoic Acid
OctamylamineSulfamidochrysoidineZirconium IodideAmaranth (Plant)
ThermolysinCadmium SelenideVirulizin®p-Nitrophenol
ErythrosineCupric ChloridePotassium Uranyl NitrateSorivudine
©2016 DrugLead US FDA&EMEA